Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction

References

• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):687–696.
   Google Scholar
• Rohla M, Pecen L, Cemin R, et al. Reclassification, thromboembolic, and major bleeding outcomes using different estimates of renal function in anticoagulated patients with atrial fibrillation. Insights from the PREFER-in-AF and PREFER-in-AF prolongation registries. Cardiovasc Qual Outcomes. 2021; 14: e006852.
   PubMed Web of Science ®Google Scholar
• Savaysa [package insert]. Basking ridge: NJ Daiichi Sankyo, Inc2 [Internet]; 2021 Accessed 10 September 2021. Available from: https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true
   Google Scholar
• Eliquis [package insert]. Princeton, NJ Bristol-Myers Squibb Co New York, NY Pfizer, Inc [Internet]; 2021 Accessed10 September 2021. Available from: https://packageinserts.bms.com/pi/pi_eliquis.pdf
   Google Scholar
• Xarelto [package insert]. Titusville: NJ Janssen Pharm Inc [Internet]; 2021 Accessed 10 September 2021. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf
   Google Scholar
• Pradaxa [package insert]. Ridgefield: CT Boehringer Ingelheim Pharm Inc [Internet]; 2021 Accessed 10 September 2021. Available from: https://docs.boehringer-ingelheim.com/PrescribingInformation/PIs/Pradaxa/Pradaxa.pdf
   Google Scholar
• Eliquis Product Information [Internet]. [cited 2021 Jan 9; 2021 Jan 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis#product-information-section
   Google Scholar
• Lixiana Product Information [Internet]. cited 2021 Jan 9]. Available from 2021 Jan 9: https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana#product-information-section
   Google Scholar
• Xarelto Product Information [Internet]. [cited 2021 Jan 9; 2021 Jan 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto#product-information-section
   Google Scholar
• U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Application number 022512. Clinical Pharmacology and Biopharmaceutics Review(s) [Internet]. 2010 Accessed 11 August 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000TOC.cfm
   Google Scholar
• Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Application number 022406. Clinical Pharmacology and Biopharmaceutics Review(s). [Internet]. 2009 Accessed 11 August 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf
   Google Scholar
• Byon W, Garonzik S, Boyd RA, et al.Apixaban : a clinical pharmacokinetic and pharmacodynamic review.Clin Pharmacokinet [Internet].2019;58(10):1265–1279.
   PubMed Web of Science ®Google Scholar
• Zhang D, He K, Herbst JJ, et al. Characterization of efflux transporters involved in distribution and disposition of Apixaban. Drug Metab Dispos [Internet]. 2013;41(4):827–835.
   PubMed Web of Science ®Google Scholar
• Hodin S, Basset T, Jacqueroux E, et al. In vitro comparison of the role of P-glycoprotein and breast cancer resistance protein on direct oral anticoagulants disposition. Eur J Drug Metab Pharmacokinet. 2018;43(2):183–191.
   PubMed Web of Science ®Google Scholar
• Sodhi JK, Liu S, Benet LZ. Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixaban disposition. Pharm Res. 2020;37(10). https://doi.org/10.1007/s11095-020-02927-4
   Google Scholar
• Kou W, Sodhi JK, Wu X, et al. Investigating intestinal transporter involvement in rivaroxaban disposition through examination of changes in absorption. Pharm Res. 2021;38(5):795–801.
   PubMedGoogle Scholar
• US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 202155. Clinical Pharmacology and Biopharmaceutical Review(s). [Internet]. 2012 Accessed 11 August 2021. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000TOC.cfm
   Google Scholar
• U.S. Food and Drug Administration. Center for drug evaluation and research. Application number 206316. Clinical Pharmacology and Biopharmaceutics Review(s). [Internet]. 2015 Accessed 11 August 2021. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000TOC.cfm
   Google Scholar
• Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Sthle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259–268.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703–712.
   PubMed Web of Science ®Google Scholar
• Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol. 2016;43(4):229–236.
   PubMed Web of Science ®Google Scholar
• Kuno T, Takagi H, Ando T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol. 2020;75(3):273–285.
   PubMed Web of Science ®Google Scholar
• Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;67(24):2888–2899.
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Caluwé R, Van Der Meersch H, et al. Safety and Ef fi cacy of Vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation : a multicenter randomized controlled trial J Am Soc Nephrol.2021;32(6);1474–1483.
   PubMedGoogle Scholar
• Chang M, Yu Z, Shenker A, et al. Effect of Renal Impairment on the Pharmacokinetics. J Clin Pharmacol. 2016;56(5):637–645 .
   PubMed Web of Science ®Google Scholar
• Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):628–636.
   PubMed Web of Science ®Google Scholar
• Mavrakanas TA, Samer CF, Nessim SJ, et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28(7):2241–2248.
   PubMed Web of Science ®Google Scholar
• Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519–1529.
   PubMed Web of Science ®Google Scholar
• Jönsson S, Simonsson USH, Miller R, et al. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. J Clin Pharmacol. 2015;55(11):1268–1279.
   PubMed Web of Science ®Google Scholar
• Doki K, Neuhoff S, Rostami-Hodjegan A, et al. Assessing potential drug–drug interactions between dabigatran etexilate and a P-Glycoprotein inhibitor in renal impairment populations using physiologically based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol. 2019;8(2):118–126.
   PubMedGoogle Scholar
• Lingineni K, Farhan N, Kim S, et al., Quantitative benefit–risk assessment of P-gp–mediated drug–drug interactions of dabigatran coadministered with pharmacokinetic enhancers in patients with renal impairment. Clin Pharmacol Ther. 109(1): 193–200. 2021.
   PubMedGoogle Scholar
• Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol. 2014;63(4):321–328.
   PubMed Web of Science ®Google Scholar
• Ismail M, Lee VH, Chow CR, et al. Minimal physiologically based pharmacokinetic and drug-drug-disease interaction model of rivaroxaban and verapamil in healthy and renally impaired subjects. J Clin Pharmacol. 2018;58(4):541–548.
   PubMedGoogle Scholar
• Greenblatt DJ, Patel M, Harmatz JS, et al. Impaired rivaroxaban clearance in mild renal insufficiency with verapamil coadministration: potential implications for bleeding risk and dose selection. J Clin Pharmacol. 2018;58(4):533–540.
   PubMed Web of Science ®Google Scholar
• Cheong EJY, Goh JJN, Hong Y, et al.Rivaroxaban with and without amiodarone in renal impairment.J Am Coll Cardiol [Internet].2018;71(12):1395–1397
   PubMedGoogle Scholar
• Grillo JA, Zhao P, Bullock J, et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos. 2012;33:99–110. : ;.(2):
   PubMed Web of Science ®Google Scholar
• Moore KT, Vaidyanathan S, Natarajan J, et al. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol. 2014;54(12):1407–1420.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yan X, Fox KAA, et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2020 Jul 1;50(1):20–29.
   PubMed Web of Science ®Google Scholar
• Solms A, Willmann S, Reinecke I, et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. J Thromb Thrombolysis [Internet]. 2020;50(1):1–11.
   PubMedGoogle Scholar
• Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Hear Rhythm. 2014;11(6):925–932.
   PubMedGoogle Scholar
• Washam JB, Hellkamp AS, Lokhnygina Y, et al. Efficacy and safety of rivaroxaban versus warfarin in patients taking nondihydropyridine calcium channel blockers for atrial fibrillation (from the ROCKET AF Trial). Am J Cardiol [Internet]. 2017;120(4):588–594.
   PubMed Web of Science ®Google Scholar
• Xu R, Tang H, Chen L, et al. Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug‐drug interactions, renal impairment and pediatric populations. Br J Clin Pharmacol. January 2021;2020. 1–11. • This study estimates the impact of concomitant DDI and renal impairment on apixaban exposure
   Google Scholar
• Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79(5):838–846.
   PubMed Web of Science ®Google Scholar
• Bhagirath V, Eikelboom J, Hirsh J, et al. Apixaban-Calibrated Anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial. TH Open. 2017;01(2):e139–45.
   Google Scholar
• Byon W, Sweeney K, Frost C, et al. Population pharmacokinetics, pharmacodynamics, and exploratory exposure – response analyses of apixaban in subjects treated for venous thromboembolism. CPT Pharmacometrics Syst Pharmacol. 2017;6:340–349.
   PubMedGoogle Scholar
• Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64(15):1541–1550.
   PubMed Web of Science ®Google Scholar
• Salazar DE, Mendell J, Kastrissios H, et al. Modeling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107(5):925–934.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–641.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288–2295. Available from.
   PubMed Web of Science ®Google Scholar
• Chang SH, Chou IJ, Yeh YH, et al. Association between use of non–vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. J Am Med Assoc. 2017 Oct 3 318(13):1250–1259.
   Google Scholar
• Hanigan S, Das J, Pogue K, et al. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020 May 1; 49(4):636–643.
   PubMedGoogle Scholar
• Zhang Y, Souverein PC, Gardarsdottir H, et al. Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: a population-based nested case–control study. Br J Clin Pharmacol. 2020 Jun 1; 86(6):1150–1164.
   PubMedGoogle Scholar
• Gumbrevičius G, Damulevičienė G, Gumbrevičiūtė M, et al. Possible interaction between dabigatran and ranolazine in patients with renal failure. Medicina. 2020;56(1):13.
   Google Scholar
• George S, Taburyanskaya M, Lewis V. Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses. Blood Coagul Fibrinolysis. 2019;30(1):42–46.
   PubMed Web of Science ®Google Scholar
• Finsterer J, Stöllberger C, Paul G, et al. Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy. Cardiovasc Ther. 2013;31(6):e111–4.
   PubMedGoogle Scholar
• Stöllberger C, Lindner K, Finsterer J. Gastrointestinal bleeding under dabigatran. J Postgrad Med. 2014;60(2):192–193.
   PubMed Web of Science ®Google Scholar
• Stöllberger C, Bastovansky A, Finsterer J. Fatal intracerebral bleeding under rivaroxaban Internet]. Int J Cardiol. 2015;201:110–112.
   PubMed Web of Science ®Google Scholar
• Jones JM, Ryan HM, Tieszen M, et al.Successful hemostasis and reversal of highly elevated PT/INR after dabigatran etexilate use in a patient with acute kidney injury.Am J Emerg Med [Internet].2016;34(4):758.e5–758.e6.
   Google Scholar
• Oladiran O, Segal J, Nwosu I, et al. A rare case of spontaneous cardiac tamponade induced by concomitant use of rivaroxaban and amiodarone. Case Reports Cardiol. 2018;2018:1–4.
   Google Scholar
• Launay M, Demartin AL, Ragey SP, et al. Severe inflammation, acute kidney injury, and drug-drug interaction: triple penalty for prolonged elimination of apixaban in patients with coronavirus disease 2019: a Grand Round. Ther Drug Monit. 2021;43(4):455–458.
   PubMedGoogle Scholar
• Skov K, Falskov B, Jensen EA, et al. Supratheraputic rivaroxaban levels: a persistent drug-drug interaction after discontinuation of amiodarone. Basic Clin Pharmacol Toxicol. 2020;127(4):351–353.
   PubMed Web of Science ®Google Scholar
• Xu R, Ge W, Jiang Q. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. Eur J Clin Pharmacol. 2018;74(6):755–765.
   PubMed Web of Science ®Google Scholar
• Huppertz A, Grond-Ginsbach C, Dumschat C, et al. Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways. BMC Pharmacol Toxicol. 2019;20(1):1–6.
   PubMedGoogle Scholar
• Harskamp RE, Teichert M, Lucassen WAM, et al. Impact of polypharmacy and P-Glycoprotein- and CYP3A4-Modulating drugs on safety and efficacy of oral anticoagulation therapy in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2019;33(5):615–623.
   PubMedGoogle Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–2352.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Scott D, Brenner B, et al. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med. 2010;363(26):2499–2510.
   PubMed Web of Science ®Google Scholar
• Murgier M, Bertoletti L, Darmon M, et al. Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry. Int J Cardiol [Internet]. 2019;291:121–126.
   PubMed Web of Science ®Google Scholar
• Murgier M, Fouillet L, Ollier E, et al. Recovery from acute kidney injury in patients with pulmonary embolism: a single-center study. Thromb Res. 2021;199(January):106–109.
   PubMedGoogle Scholar
• Bellesoeur A, Thomas-Schoemann A, Allard M, et al. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: clinical consequences. Crit Rev Oncol Hematol [Internet]. 2018;129(September 2017):102–112.
   PubMedGoogle Scholar
• Moik F, Pabinger I, Ay C. How I treat cancer-associated thrombosis. ESMO Open. 2020;5(1):e000610.
   PubMedGoogle Scholar
• Reinecke I, Solms A, Willmann S, et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. J Thromb Thrombolysis [Internet]. 2020;50(1):12–19.
   PubMedGoogle Scholar
• Godier A, Dincq AS, Line Martin AC, et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017;38(31):2431–2439.
   PubMed Web of Science ®Google Scholar
• Cavaillez T, Weinmann L, Mouton C, et al. A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a University hospital: the Retro-AOD study. Thromb Res. 2021;206(May):76–83.
   PubMedGoogle Scholar
• Towers W, Nguyen SN, Ruegger MC, et al. Apixaban and rivaroxaban anti-xa level monitoring versus standard monitoring in hospitalized patients with acute kidney injury. Ann Pharmacother [Internet]. 2021;106002802110460. DOI:https://doi.org/10.1177/10600280211046087.
   Google Scholar